---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-25-000105"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:21:27.415018+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Curis sells Erivedge royalty rights to Oberland for $2.5M; Q3 net loss narrows to $7.7M

## Summary
- Sold Erivedge IP and license rights to Oberland affiliate for $2.5M upfront and release of future royalty liability.
- Q3 2025 net loss $7.7M ($0.49/sh), improved from $10.1M loss in Q3 2024.
- Revenue from Erivedge royalties $3.2M in Q3; company will recognize gain but no future Erivedge revenues.
- Cash $9.1M as of Sep 30; expects to fund operations into early 2026.
- Nasdaq granted extension to Nov 14 to regain MVLS compliance; company believes equity now exceeds $2.5M threshold.

## SEC filing metadata
- accession: 0001108205-25-000105
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 2.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000105/0001108205-25-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000105/cris-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-25-000105
- JSON: https://secwatch.observer/filing/0001108205-25-000105.json
- Plain text: https://secwatch.observer/filing/0001108205-25-000105.txt

## Source-grounded claims
- claim_id: 61e3de6aaba0182862d1676d5686ed9301c1dfa4
  claim: CURIS INC completed a disposition involving Royalty Pharma plc for $125,000,000 (closed 2025-11-06).
  evidence_excerpt: On November 6, 2025 (the “Closing Date”), the Company completed its sale of the Erivedge Business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000105/0001108205-25-000105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.